Showing 1 - 8 of 8
The resource-based view of the firm suggests that direct control over unique assets can form the basis of sustained competitive advantage. In contrast, the papers presented in this Special Issue examine the payoffs to cross-boundary resource management. These papers demonstrate the potency of...
Persistent link: https://www.econbiz.de/10005200281
Previous studies have analyzed how incumbents may falter when they focus too narrowly on satisfying the needs of current customers at the expense of pursuing innovations that will ensure future market leadership. This paper examines this 'dilemma' faced by incumbents and considers cases where...
Persistent link: https://www.econbiz.de/10005443180
Persistent link: https://www.econbiz.de/10011131553
Developing nations are challenged to strike a balance between their patent obligations as members of the World Trade Organisation (WTO) and their drug pricing strategies. The Brazilian approach to pharmaceutical price negotiations has been strikingly effective. Describing the context of the...
Persistent link: https://www.econbiz.de/10005202494
Although pharmaceutical counterfeiting incidents can be traced back thousands of years, it has been downplayed and even dismissed by pharmaceutical manufacturers in the past. That has changed. Pharmaceutical firms are newly dedicated to eradicate counterfeits globally and spending more money on...
Persistent link: https://www.econbiz.de/10005443224
Persistent link: https://www.econbiz.de/10005412117
The debate over access to medicines has principally centered on pharmaceutical patents and prohibitively high drug prices. Although a less recognized problem, counterfeit pharmaceuticals are certainly a more insidious barrier to access. Pharmaceutical counterfeiting is an invisible threat, not...
Persistent link: https://www.econbiz.de/10005694750
Persistent link: https://www.econbiz.de/10011033925